迈威生物(688062.SH)：注射用7MW4911临床试验申请获得FDA许可

Core Viewpoint - Maiwei Biotech (688062.SH) has received FDA approval for its clinical trial application for the injectable drug 7MW4911, which is an innovative antibody-drug conjugate (ADC) targeting CDH17, a promising therapeutic target in various cancers [1] Company Summary - The FDA issued a "Study May Proceed Notification" for 7MW4911, allowing the clinical trial to commence [1] - 7MW4911 is developed based on the company's proprietary IDDC? antibody conjugation technology platform [1] - CDH17 is validated as a potential therapeutic target across multiple cancer types, showing significant overexpression in colorectal, gastric, and pancreatic cancers, which is associated with tumor invasion, metastasis, and poor prognosis [1] Industry Summary - CDH17 is expressed exclusively in the basolateral membrane of intestinal epithelial cells in normal tissues, making it an ideal target for precision intervention in gastrointestinal malignancies [1]